NCT02632448 - A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | Biotech Hunter

Enrollment

229

Participants

Timeline

Start Date

May 16, 2016

Primary Completion Date

April 14, 2025

Study Completion Date

April 14, 2025

Conditions

Solid TumorsColorectal CancerBreast CancerOvarian CancerColon CancerRectal CancerNeoplasmsEndometrial CancerSoft Tissue SarcomaTriple Negative Breast CancerPancreas CancerPancreatic Cancer

Interventions

DRUG

LY2880070

Capsules

DRUG

Gemcitabine

50 to 600 milligrams per square meter of body surface area (mg/m2)

Trial Locations (16)

10000

University Hospital Centre Zagreb, Zagreb

23000

General Hospital Zadar, Zadar

48201

Karmanos Cancer Institute, Detroit

02215

Dana Farber Cancer Institute, Boston

T2N 4N2

Tom Baker Cancer Centre, Calgary

T6G 1Z2

Cross Cancer Institute, Edmonton

V5Z 4E6

BC Cancer Agency, Vancouver

K1H 8L6

Ottawa Hospital Cancer Centre, Ottawa

M5G 2M9

University Health Network - Princess Margaret Hospital, Toronto

H2X 0A9

Centre Hospitalier de l'Université de Montréal, Montreal

H3T 1E2

Jewish General Hospital, Montreal

H4A 3J1

McGill University Health Centre, Montreal

85-796

Centrum Onkologii im. prof. F. Łukaszczyka, Bydgoszcz

80-214

Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz, Gdansk

30-348

Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o. o., Krakow

31-826

Szpital Specjalistyczny im. L. Rydygiera w Krakowie sp. z o. o., Krakow

All Listed Sponsors

lead

Esperas Pharma Inc.

OTHER